explore -WSS

explore

author：hotspot 2025-10-01 23:43:21 - browse：66

Illumina said Monday afternoon that its board of directors had approved a spin-off of its cancer test subsidiary Grail, signaling that a nearly four-year-long, $8 billion saga will finally draw to a close this month.

Shares in the newly independent Grail are expected to be distributed on June 24, Illumina said in a statement. Illumina will retain a 14.5% stake in the company, which will trade under the ticker $GRAL.

It’s the second time Illumina has spun off Grail, which initially began as a unit within the DNA sequencing giant in 2015. Illumina turned it into an independent company the following year but then agreed to reacquire it for $8 billion in September 2020.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： After affirmative action ruling, medical educators look to 'holistic review'
Next article： Deliver public health messages at the right time

focus

entertainment

WSS

AI for drug discovery: Experts on separating hype from reality

Empower primary care with adequate payments and technology

A common UTI test for kids haunts adults as a traumatic 'nightmare'

FDA panel endorses Alnylam’s heart drug — after picking it apart

Crowdfunding for medical bills sidesteps core problem, author says

Can gargling with Listerine treat gonorrhea of the mouth?

hotspot

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

Medical records are filled with copy

PBM executives asked to testify by House panel

Novavax promises a turnaround & Lilly roils the obesity market

Sepsis can kill a child within hours. Here's how hospitals are fighting back

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Private equity could exacerbate cardiology's overuse problem, experts fear

In age of alternative facts, a scholarly course on calling out crap

Generate Biomedicines machine learning biotech raises $273M

Continuity nursing helped my family in our darkest PICU moments

Will the IRA bring competition to the biologics market?

hotspot

Brain MRIs reveal impact of 'toxic stress' on Black children

Long Covid needs a new name — and a new frame

The effects of a landmark ruling on DNA ownership are becoming clearer

Readout Newsletter: PTC, Dyne, Rapport, Cytokinetics news

New Covid vaccine is recommended for everyone 6 months or older

FDA panel endorses Alnylam’s heart drug — after picking it apart

knowledge

focus

entertainment

focus